BeiGene Gets Green Light for $3 Billion Shanghai STAR IPO
publication date: Nov 17, 2021
Beijing's BeiGene was approved to stage a $3 billion IPO on Shanghai’s STAR Exchange, the company's third listing. Previously, the company completed an $182 million IPO on NASDAQ in 2016 and a $900 million Hong Kong IPO in 2018. It will be the first biopharma to list on the three exchanges. The China Securities Regulatory Commission (CSRC) signed off on the IPO this week, the last requirement for the process. Founded in 2010, BeiGene focuses on developing molecularly targeted and immuno-oncology drug candidates. More details....
Stock Symbols: (NSDQ: BGNE; HK: 06160)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.